Metallic implant and process for treating a metallic implant

ABSTRACT

A process for treating a metallic implant consisting essentially of treating the metallic implant with a solution of hydrofluoric acid, which solution has a pH between 1.6 and 3.0.

This application is a continuation-in-part of U.S. Ser. No. 08/446,675,filed Sep. 20, 1996, which is a national phase of applicationPCT/SE94/01225, filed Dec. 19, 1994, which are hereby incorporated byreference.

TECHNICAL FIELD

The present application relates to biocompatible metallic bone implants,preferably made of titanium or an alloy thereof, and to a method fortreating metallic implants to enhance their biocompatibility.

BACKGROUND

A commonly used method for implanting metallic implants into bone tissueis a two stage procedure involving in a first operation surgicallyplacing the implant into the bone tissue, where it is then allowed torest unloaded and immobile for a healing period of three months or morein order to allow the bone tissue to grow onto the implant surface so asto permit the implant to be well attached to the bone tissue, the cut inthe soft tissue covering the implant site being allowed to heal over theimplant, and in a second operation opening the soft tissue covering theimplant and attaching the functional parts to the implant. Thistwo-stage procedure is often used in connection with dental implants,one reason being that it minimized the risk of infection of the implantsite from the oral cavity. In some orthopedic applications the abovetwo-stage surgery may not be necessary since most orthopaedic implantsdo not penetrate the soft tissue. A prolonged healing period is howeverstill considered necessary since any movements of the implant in theweeks and months following surgery may endanger the final attachment ofthe implant to the bone tissue.

The above procedure is for instance described in Brånemark et al:“Osseointegrated Implants in the Treatment of Edentulous Jaw, Experiencefrom a 10-year period”, Almquist & Wiksell International,Stockholm-Sweden.

However, the fact that the implant may not be loaded means that thefunctional parts of the implant may not be attached to the implantand/or used during the healing period of three months or more. In viewof the discomfort associated with this, it is desirable to minimize thetime period necessary for the above-mentioned first stage and in somecases, for instance in certain orthopaedic application, substantiallydispense with said first stage and perform the entire implantationprocedure in a single operation.

An object of the present invention is to provide an implant withimproved rate of bone tissue attachment such that the post-surgeryhealing period described above may be reduced.

Some of the metals or alloys used for bone implants are capable offorming a strong bond with the bone tissue, a bond which may be asstrong as the bone tissue per se, sometimes even stronger. The mostnotable example of this kind of metallic implant material is titaniumand allows of titanium whose properties in this respect have been knownsince about 1950. This bond between the metal and bone tissue has beentermed “oseointegration” by Brånemark et al.

Although this bond between titanium and bone tissue is comparativelystrong, in some applications it is desirable to enhance the bond betweenmetal and bone tissue.

There are to date several methods for treating implants made of titaniumin order to obtain a better attachment of the implant. Some of theseinvolve altering the topography of the implant, for example by creatingrelatively large irregularities on the implant surface in order toobtain a better mechanical retention and to increase the area ofattachment, by for example plasma spraying, blasting or etching.Although the retention may be improved, the time necessary for theosseointegration process may be longer since the bone tissue would haveto grow into the irregularities in the surface.

Other methods involve altering of the chemical properties of the implantsurface. For example one such method involves the application of a layerof ceramic material such as hydroxyapatite to the implant surface, interalia in order to stimulate the regeneration of the bone tissue. Ceramiccoatings however may be brittle and may flake or break off from theimplant surface, which may in turn lead to the ultimate failure of theimplant.

U.S. Pat. No. 4,330,891 could perhaps be said to combine each of theabove, in that the provision of an element with a micro-pitted surfacewhich micro-pits are within a certain diameter range, is said to effectimproved properties as regards acceptance of the carrier element, andprimarily improved durability of the healthy ingrowth of the element dueto its biological quality.

A further object of the invention is to provide an implant forming astronger bond with the bone tissue.

Short description of the inventive concept.

It has been found that the desired metallic implant may be obtained bytreating a metallic surgical implant with an aqueous solution ofhydrofluoric acid.

SHORT DESCRIPTION OF THE APPENDED DRAWINGS

FIG. 1 is diagram illustrating the pushout force as well as the fluorineand oxygen content of an implant surface treated with 0.2% HF as afunction of the treatment time.

FIG. 2 is a SEM photograph of an implant surface treated with 0.2% HFfor 30 seconds, in a magnification of 10 000 times,

FIG. 3 is the implant surface in FIG. 2, in 52 000 times magnification,

FIG. 4 is a SEM photograph of an implant, in 10 000 times magnification,having been treated with 0.2% HF for 90 seconds,

FIG. 5 is the surface of FIG. 4 in 52 000 times magnification.

FIG. 6 is SEM photograph of an untreated implant surface in 52 000 timesmagnification.

FIGS. 7-9 are diagrams illustrating the effects of different treatmentsby means of calcium precipitation tests.

THE INVENTION

Accordingly, in a first aspect the present invention provides a processfor the treatment of a metallic implant comprising treating the metallicimplant with an aqueous solution of hydrofluoric acid, which solution isof pH 1.6 to pH 3.

Alternatively stated in terms of concentration, the present inventionprovides a process for the treatment of a metallic implant comprisingtreating the metallic implant with an aqueous solution of hydrofluoricacid of concentration up to 3.0%

Preferably the metallic implant is made of commercially pure titanium oran alloy of titanium. The implants may be standard, blasted or other.

Preferably, the concentration of hydrofluoric acid is 0.01% to 3.0% suchas 0.1% to 2.0%. Most preferably the concentration of hydrofluoric acidis about 0.2% to about 2.0% especially 0.2% to 0.5% and most preferablyabout 0.2%.

The treatment of the present invention may be carried out for anysuitable length of time. Preferably the treatment is carried out for atleast 10 seconds such as 10 seconds to 6 hours, for example 10 secondsto 2 minutes such as 10s to 50s, or 30s, 60s, or 2 minutes.

The treatment may be carried out in any suitable manner, for example byimmersing the implant in the treatment solution for a period of time,and with or without agitation. Varying temperatures may be employed,parameters such as temperature and time may be selected according to theconcentration of the treatment solution and the other processparameters. The treatment is conveniently carried out at standardpressure, but elevated pressures may be used where desired. Preferably,treatment is carried out at around standard temperature and pressure.

In a preferred embodiment the present invention provides a process forthe treatment of a metallic implant comprising treating the metallicimplant with a 0.1-2.0% aqueous solution of hydrofluoric acid at roomtemperature for a period of up to 3 minutes.

The treatment solution of the present invention may be simply prepared,by duluting concentrated HF with distilled water.

Prior to treatment, the implant material may be cleaned by standardtechniques such as are well known in the art.

After treatment, the implant material may be washed in distilled waterand kept under sterile conditions.

Implants treated in accordance with the present invention show a strongcontact with bone, as demonstrated in “push-out” tests described herein,and a high degree of bone contact in the spongiosa cancerous region. Newbone will form on the implant surface in the cancellous region and willmore or less cover the implant in this area. Such a response is notobserved in untreated control groups. The degree of bone contactindicates bone growth in the spongiosa cancellous region.

The process specified therefore beneficially effects the surface of theimplant so as to improve the biocompatibility (specifically the rate ofbone tissue attachment and strength or bonding) of the implant. While wedo not wish to be limited to the expression of theories herein, theimproved biocompatibility is thought to be due, at least in part, tofluoride being retained on the surface of the implant. As such,treatments other than with hydrofluoric acid, which provide fluorideions, could be expected to have some effect on the biocompatibility ofmetallic implants. Treatment with sodium fluoride is known from ourprior application WO 94/13334. In a second aspect this inventiontherefore provides a process for treating a metallic implant comprisingtreating the implant with an aqueous solution containing fluoride ionsin a concentration of up to 3%, said aqueous solution being free ofsodium ions. The preferred treatment parameters correspond to thosepreferred in the hydrofluoric acid treatment described herein.

Preferably no significant etching of the implant surface occurs with thepresent treatment. Most preferably, there is substantially no etching ofthe implant surface.

Thus, metallic implants treated according to the invention preferablyhave essentially the same morphology as the surfaces of the implantsbefore said treatment. By “essentially the same morphology” is intendedthat the surfaces of the implants only undergo minor morphologicalchanges or no morphological changes at all during the chemical treatmentaccording to the invention.

Implants treated by the process of the present invention are alsoprovided herein. Therefore in a third aspect the present inventionprovides a metallic implant which has been treated with an aqueoussolution of hydrofluoric acid according to the processes describedherein.

As stated hereinabove, the beneficial effect of the present invention isthought to be related to fluoride being retained on the surface of thetreated implant. The treatment described is a surface treatment whichaffects the surface properties of the implant although at this stage itis not possible to define the surface characteristics of the treatedimplant more than to say that the desired characteristics are providedby the present process.

In fourth aspect therefore the present invention provides a metallicimplant having a surface equivalent to the surface of an implant whichhas been treated with an aqueous solution of hydrofluoric acid accordingto the processes described herein.

The metallic implant according to the invention or treated according tothe invention may be an implant constituted of only a metal or a metalalloy. It may also be an implant constituted of a metal or a metal alloycovered at the surface, at least partially, by a layer, preferably athin layer, of an oxide.

In a fifth aspect the present invention thus provides a process fortreatment of metallic implants, such as implants of titanium or atitanium alloy, covered at least partially with an oxide layer.

When a metallic implant, and especially an implant of titanium ortitanium alloy, is exposed to surrounding air, a titanium oxide layer isoften formed on the surface due to oxidation of the metal, such astitanium, by the oxygen in the air.

This oxide covered metallic implant is treated with the above describedprocess in order to provide a fluoride or fluorine containing layer onthe surface of the implant. In order to obtain this fluoride or fluorinecontaining surface it is possible to use any source of fluoride ions orfluorine, such as an aqueous solution comprising fluoride ions, providedthat the solution is free of sodium and sodium ions. It is thus possibleto use a solution of hydrofluoric acid, or of a fluoride such asfluoride selected from the group consisting of lithium fluoride, cesiumfluoride, potassium fluoride, ammunonium fluoride and stannous fluoride,or a combination of several of these sources.

The treatment period needed in order to obtain the desired content offluoride or fluorine in the surface layer is due to the thickness of theoxide layer on the metallic core of the implant.

According to a sixth aspect a metallic implant with a fluoride orfluorine containing surface may be further treated with a solutioncontaining calcium ions, in order to further improve thebiocompatibility.

This treatment with calcium ions leads to the deposition of calcium ontothe surface of the metallic implant or onto the oxide layer on themetallic implant.

Preferably, the metallic implants or the oxide-covered implants areplaced or dipped in the solution for an appropriate period of time, suchas a period of 10 seconds to 10 minutes.

As calcium ion source it is possible to use any calcium containingcompound that provides calcium ions in solution. The solution containingcalcium ions may thus be an aqueous solution of calcium fluoride,calcium phosphate, calcium acetate, calcium chloride or any otherwater-soluble calcium salt. The solution may either be a diluted orsaturated solution.

Optionally, this calcium deposition may be obtained through naturallyoccurring biological processes once the implant is inserted into thebone tissue. Since calcium is present in the body, calcium will bedeposited on the surface of an implant once it is implanted into thebody. However, this natural calcium deposition process is slower thanthe above described treatment. According to this aspect of the inventionit is preferable to perform the calcium treatment before implantation.

Another was of describing the effect of the present treatment is bymeans of the induction of calcium phosphate precipitation. This is an invitro test described in “Damen, Ten Cate, Ellingsen, Induction ofCalcium Precipitation by Titanium dioxide, Journal of Dental Research,October 1991”. In this method an implant is immersed in a saturatedsolution of calcium phosphate.

Depending on the surface, precipitation of calcium onto the implantoccurs. The concentration of Ca++ is monitored and the time delay (theinduction time) until precipitation occurs is measured. The rationalebehind this test is the assumption that there is a correlation betweenthe affinity of the implant surface towards the calcium ions and thebiocompatibility of the implant surface in bone tissue. Implants treatedin accordance with the present invention show an affinity to calciumions in this test. Accordingly, in a fourth aspect the present inventionprovides an implant treated with hydrofluoric acid in accordance withthe present invention, which implant precipitates calcium ions from asaturated solution of calcium phosphate.

The following Examples illustrate the invention.

EXAMPLES Example 1

Seven surgical implants, commercially pure (c.p.) titanium, 5 mm inlength and generally conical in shape having a diameter at one end of 3mm and at the other end 2 mm, were prepared by machining using a“Maximat super 11” (TM) turning lathe. Therefore the area of the conicalsides of the implant, i.e. the part of the implant to be located in thebone, is 39 mm².

Each implant was cleaned according to a well-known cleaning procedureinvolving the following steps:

1. Treatment with trichloroethylene with ultrasonic treatment, for 15minutes.

2. Rinsing in absoute ethanol, for 10 seconds.

3. Three successive treatments with ethanol with ultrasonic treatment,each for 10 minutes.

Each cleaned implant was sterile packaged in a Mediplast (TM) sterileenvelope, and autoclaved in a Citomat 162 (TM) (LIC Company) autoclave,at 120 C for 30 minutes.

A HF bath was prepared simply by diluting concentrated HF with distilledwater, to give 0.2% solution. The pH of the bath was 2.1.

Seven implants, prepared, cleaned, sterile packaged and autoclavedexactly as described above, were removed from their sterile packages,placed in the HF treatment bath and left there for two minutes.Thereafter each was washed three times in a bath of distilled water, forperiods of 30 seconds each wash. After being allowed to dry at roomtemperature, each implant was transferred to a Mediplast (TM) sterileenvelope to await surgical implantation.

Implant Study

Chinchila rabbits were used as test animals. The rabbits were randomlydistributed regarding sex, but all had a weight of 2.5 kg at the startof the study. Each animal was sedated by injection using a combinationof fluanozonium 1.0 mg/kg and fentanylium 0.02 mg/kg (Hypnorm, JannsenPharmaceuticals, Belgium) and locally anesthetized withxylocaine/adrenaline (AB Astra). Two cavities were drilled in eachrabbit's right ulna, using standardized bores designed to providecavities into which the conical implants would exactly fit. Treated anduntreated implants were placed in the cavities of each rabbit, usingtitanium tweezers so as to avoid the influence of other metals, and leftfor sixty days.

At the end of sixty days the rabbits were sacrificed by injection withpentobarbital natrium, and the ulna's removed and placed in sterilephysiological saline to await a “push-out” test the same day.

An Instron model 1121 tensile testing machine (Instron, U.K.) inter aliacomprising a support jig and a ram adjusted for a load range of 0-200 N,was employed to measure the force needed to separate each implant frombone. Milling tracks, to fit the support jig, were made in the specimento be tested, in the bone surrounding the larger end of the implant, andthe specimen was placed on the support jig. The ram lowered at a speedof 1 mm/min., and the force required to separate the implant from thebone was recorded.

This recorded force gives a direct assessment of the strength ofconnection of implant and bone, the higher the required force thestronger the connection.

The results are recorded in Table 1. TABLE 1 Recorded force (N)Untreated implants Treated implants 1 18.1 1 84.1 2 59.2 2 96.0 3 44.7 364.2 4 39.2 4 62.7 5 59.5 5 64.9 6 6.0 6 89.5 7 8.5 7 89.5 mean 33.6mean 78.7

The much greater strength of bone connection with implants treated inaccordance with the present invention is apparent from the above.

Histological examination demonstrated that the implants according toExample 1 were surrounded even in the ulna's spongiosa by a thick layerof newly formed bone which was in close contact with the implants. Incontrast the untreated implants, i.e. those according to the ComparativeExamples, were only partly covered, by a thin bone layer, in thespongiosal area.

Example 2

Reference implants were made of titanium grade 3, and were made byturning at an average speed of about 7 meters per minute. No cuttingfluid was used. The cutting tool was made of high speed steel.

The reference implant surface was cleaned by a standard cleaningprocedure involving the following steps:

1. Treatment with trichloroethylene with ultrasonic treatment for 15minutes.

2. Rinsing in absolute ethanol for 10 seconds.

3. Three successive treatments with ethanol with ultrasonic treatment,each for 10 minutes. Each cleaned implant should then be sterile packagein a Mediplast (TM) sterile envelope and autoclaved in a Citomat 62 (TM)(LIC Company) autoclave at 120° C. for 30 minutes.

The result of an experiment in which the force necessary for removing(pushing out) substantially conical, unthreaded implants treated in 0.2%aqueous solution of hydrofluoric acid at room temperature for differenttime periods is illustrated in the diagram in FIG. 1. The implants hadbeen manufactured to have a diameter of 2 mm at one end, 3 mm at theother end and an overall length of 5 mm and were made from titaniumgrade 3 and cleaned and sterilized in accordance with the aboveprocedures for treating the reference implant surface. The treatmenttimes were 10 seconds, 30 seconds, 60 seconds, 90 seconds, 120 secondsand 180 seconds. Pushout tests were made and the pushout forces weremarked in the diagram for each treatment time except 90 and 180 seconds.The values for an untreated control specimen are also given in thediagram as having a treatment time of 0 seconds.

Each value for the pushout test results are a mean of the values forfour implants implanted in the tibia of a respective rabbit and left toheal into the bone tissue for two months.

The reference implants were also treated in the way described above. Thecontent of fluorine and of oxygen as measured in the surface of thetreated implants are marked in the diagram for each treatment time.

An Instron model 1121 tensile testing machine (Instron, U.K.) set to thesame parameters as the machine in Example 1 was used and the contents offluorine and oxygen were measured by means of an Electron microprobe(CAMECA camebax) at SINTEF/SI in Oslo. The results as measured with thisequipment were F % 0% 0 sec 0.01 5.1 10 sec 0.15 5.5 30 sec 0.11 5.8 60sec 0.17 5.7 90 sec 0.2 9.4 120 sec 0.23 8.4 180 sec 0.16 11.0

The diagram In FIG. 1 illustrates higher values for the pushout testsresulting from treatment times varying between 10 and 50 seconds with apeak value at 30 seconds. The values for the remaining treatment timesand the untreated control specimens are lower although the treatedimplants generally have higher values than the untreated ones. Thevalues for the oxygen (5.5 to 5.8%) and fluorine content (0.11 to about0.15%) of the surface of the implants for the treatment times between 10and 50 seconds are lower than the corresponding values for the othertreatment times.

The pushout tests were made after a time period which was as short astwo months. The rapid increase of the strength of the bond results inthat the healing period necessary for reaching a given strength of thebone is shortened. The use of the treatment according to the inventionthus facilitates the use of one-stage surgical procedures particularlyin orthopaedics, since the time the patient must remain inactive isshortened.

FIG. 2 illustrates how the implant surface seems to be largelyunaffected by the treatment involving a HF-concentration of 0.2% and atreatment time of 30 sec, no effect being discernable in a magnificationof 10 000 times (the original tooling marks not being affected at all).This photograph shold be compared with the photograph in FIG. 4, in 10000 times magnification, showing a surface which has been treated longer(90 seconds) in 0.2% HF and in which the marked change in the surface bythe treatment in question is illustrated.

FIG. 3, which shows the surface in FIG. 2 in a magnification of 52 000times, should be compared with FIG. 6, which shows an untreated surfacein a magnification of 52 000 times, and with FIG. 5, which shows thesurface of FIG. 4 in a magnification of 52 000 times. As is evident, thesurface treated with 0.2% solution is only slightly affected in regardof the morphology, the tooling marks still being discernable, whereasthe surface treated for a longer period of time is distinctly alteredand covered with a porous layer. It is believed that the best embodimentof the invention involves surfaces whose morphology only are slightlyaffected by the treatment although other treated surfaces also may havethe effect expected from the invention.

In the above push out test implants manufactured and treated in the sameway as the reference implant surface were used. It should however benoted that the metallic implants to be sued in the clinical situationand/or in research of course can be manufactured of any metal andtreated in any way within the scope of the claims provided the implantsurface is equivalent to the reference surface in regard of the contentof fluorine.

Example 3

Another way of describing the effect of treatment is by means of theinduction of Calcium Phosphate Precipitation. This is an in vitro testdescribed in “Damen, Ten Cate, Ellingsen, Induction of CalciumPrecipitation by titanium Dioxide, Journal of Dental Research, October1991”. In this method an implant is immersed in a saturated solution ofcalcium phosphate. Depending on the surface, precipitation of calciumonto the implant occurs. The concentration of Ca++ is monitored and thetime delay (the induction time) until precipitation occurs is measured.The rationale behind this test is the assumption that there is acorrelation between the affinity of the implant surface towards thecalcium ions and the biocompatibility of the implant surface in bonetissue. The results of the test are illustrated in the appendeddiagrams, FIGS. 7-10. The concentration of Ca++ is given on the Y-axis(2.00 e-1 means 2.00×10⁻¹ etc). The test time is given on the X-axis inminutes.

The implants in the test had been treated as follows: Concentration, HFTreatment time 0.05% 180 sec 0.15% 180 sec 0.2% 30, 60, 120 sec 0.5% 60sec 2.0% 60 secUntreated control implants were also tested.

The test solution was a solution comprising 7.5 mM KH₂PO₄ and 50 mMHEPES (pH 7.2) added to a solution comprising 1 mM CaCl₂ and 50 mM HEPES(pH 7.2). HEPES is a standard buffering solution. The temperature of thesolution during the tests was 37 degrees centigrade.

The concentration of the calcium in the solution after immersion of therespective implant is measured at a calcium selective electrode during atime period of 5 hours. As indicated in the diagrams, there is noprecipitation in solutions in which the control implants and implantstreated with 0.15% HF have been immersed during the 5 hour immersiontime, see FIG. 7.

For certain of the implants treated with 0.2% HF there was precipitationin the test solution as early as 4 hours after the immersion. Theseimplants had been treated with HF for 60 and 120 sec. Implants havingbeen treated with 0.2% HF for 30 sec caused precipitation, but not untilabout 5 hours immersion time, see FIG. 8.

Implants treated with 0.5% HF for 60 sec caused precipitation at about 4hour immersion time, whereas the implants treated with 2.0% HF for 60sec caused precipitation both before and after 5 hour immersion time.

According to these data there would seem to be ranges of HFconcentrations and treatment times giving the desired result, with acentral range around 0.2-0.5% giving better results. These data to someextent complement the data in the previous examples, and it consequentlyis believed that the implants according to the invention also can bedefined by means of this test, which is a relatively simple one.

Accordingly, an implant according to the invention can be defined as animplant having been treated with HF and which causes precipitation ofcalcium ions onto the implant surface from a solution comprising 7.5 mMKH₂PO₄ and 50 mM HEPES (pH 7.2) added to a solution comprising 1 mMCaCl₂ and 50 mM HEPES (pH 7.2), the temperature of the solution duringthe tests being 37 degrees centigrade.

Example 4

Screwshaped implants having been implanted into bone tissue in the ulnaof rabbits for 2 months were removed by torque and histological studiesof the implant surface were made.

For a standard implant treated in 0.2% HF for 120 sec, the bone contactwas 63.3%, whereas the bone contact for a standard, untreated controlimplant was only 42.4%.

For an implant blasted with particles of titanium dioxide and treated in0.2% HF for 90 sec the bone contact was 53.5% whereas the bone contactfor a similarly blasted, but untreated implant was 37.3%.

The above values are mean values for 4-8 implants.

The bone contact was more pronounced in the spongiosa for the treatedimplants.

The treated implants consequently show a pronounced improvement incomparison with the untreated implants.

1. A process of treating a metallic bone implant consisting essentiallyof treating the metallic bone implant with a solution of hydrofluoricacid, which solution has a pH in the range of 1.6 to 3.0.
 2. A processof treating a metallic bone implant consisting essentially of treatingthe metallic bone implant with a solution of hydrofluoric acid in whichthe concentration of hydrofluoric acid is greater than 0%. and up to 3%.3. A process as claimed in claim 2 in which the concentration ofhydrofluoric acid is 0.1% to 2.0%.
 4. A process as claimed in claim 2 inwhich the concentration of hydrofluoric acid is 0.2% to 2.0%.
 5. Aprocess as claimed in claim 2 in which the concentration of hydrofluoricacid is approximately 0.2%.
 6. A process as claimed in claim 1 in whichthe treatment is carried out for a period of at least 10 seconds.
 7. Aprocess as claimed in claim 6 in which the treatment is carried out fora period of 10 seconds to 2 minutes.
 8. A process of treating a metallicbone implant consisting essentially of treating the metallic boneimplant with an aqueous solution of hydrofluoric acid in which theconcentration of hydrofluoric acid is 0.1% to 2.0% at room temperaturefor a period of up to 3 minutes.
 9. A process as claimed in claim 8 inwhich the concentration of hydrofluoric acid is 0.2% to 2.0%.
 10. Aprocess of treating a metallic bone implant consisting essentially oftreating the metallic bone implant with an aqueous solution containingfluoride ions in a concentration of greater than 0% and up to 3% saidaqueous solution being free from sodium and sodium ions.
 11. A metallicbone implant treated according to a process as claimed in claim
 1. 12. Ametallic bone implant as claimed in claim 11, which implant precipitatescalcium ions from a saturated solution of calcium phosphate.
 13. Ametallic implant adapted for osseointegration in bone tissue,characterized in that the surface of said metallic implant contains oneor both of fluorine and fluoride ions in an amount equivalent to thatobtained by means of treatment of said implant surface with a 0.2%aqueous solution of hydrofluoric acid at room temperature for 10-15seconds.
 14. Metallic implant according to claim 13, characterized inthat said metallic implant is made of commercially pure titanium or analloy of titanium.
 15. The metallic implant according to claim 14,characterized in that the surface of said metallic implant contains oneor both of fluorine and fluoride ions in an amount equivalent to thatobtained by means of a treatment with a 0.2% aqueous solution ofhydrofluoric acid at room temperature for 30 seconds.
 16. A process oftreating a metallic bone implant consisting essentially of treating theimplant with a solution of hydrofluoric acid which has a pH in the rangeof 1.6 to 3.0 for a duration sufficient for the implant to be able topromote a greater degree and strength of bone tissue contact therewiththan an untreated implant after a predetermined implantation time in abone tissue structure.
 17. A process of treating a metallic bone implantconsisting essentially of treating the implant with a solution ofhydrofluoric acid which has a concentration of hydrofluoric acid greaterthan 0% and up to 3% for a duration sufficient for the implant to beable to promote a greater degree and strength of bone tissue contacttherewith than an untreated implant after a predetermined implantationtime in a bone tissue structure.
 18. A process of treating a metallicbone implant consisting essentially of treating the implant with anaqueous solution which contains fluoride ions in a concentration greaterthan 0% and up to 3% and is free from sodium and sodium ions for aduration sufficient for the implant to be able to promote a greaterdegree and strength of bone tissue contact therewith than an untreatedimplant after a predetermined implantation time in a bone tissuestructure.
 19. The process of claim 2 wherein the concentration ofhydrofluoric acid is greater than 0.01%.
 20. A process as claimed inclaim 1 in which the surface of the metallic bone implant after thetreatment with the hydrofluoric acid solution has essentially the samemorphology as the surface of the implant before said treatment.
 21. Aprocess as claimed in claim 2 in which the surface of the metallic boneimplant after the treatment with the hydrofluoric acid solution hasessentially the same morphology as the surface of the implant beforesaid treatment.
 22. A process as claimed in claim 8 in which the surfaceof the metallic bone implant after the treatment with the hydrofluoricacid solution has essentially the same morphology as the surface of theimplant before said treatment.
 23. A process as claimed in claim 10 inwhich the surface of the metallic bone implant after the treatment withthe aqueous solution containing fluoride ions has essentially the samemorphology as the surface of the implant before said treatment.
 24. Aprocess as claimed in claim 16 in which the surface of the metallic boneimplant after the treatment with the hydrofluoric acid solution hasessentially the same morphology as the surface of the implant beforesaid treatment.
 25. A process as claimed in claim 17 in which thesurface of the metallic bone implant after the treatment with thehydrofluoric acid solution has essentially the same morphology as thesurface of the implant before said treatment.
 26. A process as claimedin claim 18 in which the surface of the metallic bone implant after thetreatment with the aqueous solution containing fluoride ions hasessentially the same morphology as the surface of the implant beforesaid treatment.
 27. A process as claimed in claim 1, wherein saidmetallic bone implant has a surface layer constituted by a metallicoxide.
 28. A process as claimed in claim 2, wherein said metallic boneimplant has a surface layer constituted by a metallic oxide.
 29. Aprocess as claimed in claim 8, wherein said metallic bone implant has asurface layer constituted by a metallic oxide.
 30. A process as claimedin claim 10, wherein said metallic bone implant has a surface layerconstituted by a metallic oxide.
 31. A process as claimed in claim 16,wherein said metallic bone implant has a surface layer constituted by ametallic oxide.
 32. A process as claimed in claim 17, wherein saidmetallic bone implant has a surface layer constituted by a metallicoxide.
 33. A process as claimed in claim 18, wherein said metallic boneimplant has a surface layer constituted by a metallic oxide.
 34. Aprocess as claimed in claim 27, wherein said metallic bone implant isconstituted by titanium or a titanium alloy, and said metallic oxide isa titanium oxide.
 35. A process as claimed in claim 28, wherein saidmetallic bone implant is constituted by titanium or a titanium alloy,said metallic oxide is a titanium oxide.
 36. A process as claimed inclaim 29, wherein said metallic bone implant is constituted by titaniumor a titanium alloy, and said metallic oxide is a titanium oxide.
 37. Aprocess claimed in claim 30, wherein said metallic bone implant isconstituted by titanium or a titanium alloy, and said metallic oxide isa titanium oxide.
 38. A process as claimed in claim 31, wherein saidmetallic bone implant is constituted by titanium or a titanium alloy,and said metallic oxide is a titanium oxide.
 39. A process as claimed inclaim 32, wherein said metallic bone implant is constituted by titaniumor a titanium alloy, and said metallic oxide is a titanium oxide.
 40. Aprocess as claimed in claim 33, wherein said metallic bone implant isconstituted by titanium or a titanium alloy, and said metallic oxide isa titanium oxide.
 41. A process as claimed in claim 1, comprising afurther step, performed after said treatment with the hydrofluoric acid,wherein the implant is treated with a solution comprising calcium ions.42. A process as claimed in claim 2, comprising a further step,performed after said treatment with the hydrofluoric acid, wherein theimplant is treated with a solution comprising calcium ions.
 43. Aprocess as claimed in claim 8, comprising a further step, performedafter said treatment with the hydrofluoric acid, wherein the implant istreated with a solution comprising calcium ions.
 44. A process asclaimed in claim 10, comprising a further step, performed after saidtreatment with the hydrofluoric acid, wherein the implant is treatedwith a solution comprising calcium ions.
 45. A process as claimed inclaim 16, comprising a further step, performed after said treatment withthe hydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 46. A process as claimed in claim 17,comprising a further step, performed after said treatment with thehydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 47. A process as claimed in claim 18,comprising a further step, performed after said treatment with thehydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 48. A process as claimed in claim 34,comprising a further step, performed after said treatment with thehydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 49. A process as claimed in claim 35,comprising a further step, performed after said treatment with thehydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 50. A process as claimed in claim 36,comprising a further step, performed after said treatment with thehydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 51. A process as claimed in claim 37,comprising a further step, performed after said treatment with thehydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 52. A process as claimed in claim 38,comprising a further step, performed after said treatment with thehydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 53. A process as claimed in claim 39,comprising a further step, performed after said treatment with thehydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 54. A process as claimed in claim 40,comprising a further step, performed after said treatment with thehydrofluoric acid, wherein the implant is treated with a solutioncomprising calcium ions.
 55. A metallic implant adapted forosseointegration in bone tissue, characterized in that the surface ofsaid metallic implant contains one or both of fluorine and fluoride ionsin an amount equivalent to that obtained by means of treatment of saidimplant surface with a 0.2% aqueous solution of hydrofluoric acid atroom temperature for a period of 10 seconds to 2 minutes.
 56. A metallicimplant according to claim 35, wherein said metallic implant is made ofcommercially pure titanium or an alloy of titanium.
 57. A metallicimplant adapted for osseointegration in bone tissue, characterized inthat the surface of said metallic implant contains one or both offluorine and fluoride ions in an amount equivalent to that obtained bymeans of treatment of said implant surface with a 0.2% aqueous solutionof hydrofluoric acid at room temperature for a period of 10 seconds to 2minutes immediately followed by rinsing with water.
 58. A metallicimplant according to claim 57, wherein said metallic implant is made ofcommercially pure titanium or an alloy of titanium.
 59. A metallicimplant according to claim 13, wherein the surface of said implant alsocontains calcium.
 60. A metallic implant according to claim 14, whereinthe surface of said implant also contains calcium.
 61. A metallicimplant according to claim 55, wherein the surface of said implant alsocontains calcium.
 62. A metallic implant according to claim 56, whereinthe surface of said implant also contains calcium.
 63. A metallicimplant according to claim 57, wherein the surface of said implant alsocontains calcium.
 64. A metallic implant according to claim 58, whereinthe surface of said implant also contains calcium.
 65. A process asclaimed in claim 1, which improves the biocompatibility of in bonetissue.
 66. A process as claimed in claim 1, which improves the rate ofbone tissue attachment of said metallic bone implant.
 67. A process asclaimed in claim 2, which improves the biocompatibility of in bonetissue.
 68. A process as claimed in claim 2, which improves the rate ofbone tissue attachment of said metallic bone implant.
 69. A process asclaimed in claim 8, which improves the biocompatibility of in bonetissue.
 70. A process as claimed in claim 8, which improves the rate ofbone tissue attachment of said metallic bone implant.
 71. A process asclaimed in claim 10, which improves the biocompatibility of in bonetissue.
 72. A process as claimed in claim 10, which improves the rate ofbone tissue attachment of said metallic bone implant.
 73. A process asclaimed in claim 16, which improves the biocompatibility of in bonetissue.
 74. A process as claimed in claim 16, which improves the rate ofbone tissue attachment of said metallic bone implant.
 75. A process asclaimed in claim 17, which improves the biocompatibility of in bonetissue.
 76. A process as claimed in claim 17, which improves the rate ofbone tissue attachment of said metallic bone implant.
 77. A process asclaimed in claim 18, which improves the biocompatibility of in bonetissue.
 78. A process as claimed in claim 18, which improves the rate ofbone tissue attachment of said metallic bone implant.